

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant x

Filed by a Party other than the Registrant o

Check the appropriate box:

- o Preliminary Proxy Statement
- o **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- o Definitive Proxy Statement
- x Definitive Additional Materials
- o Soliciting Material under §240.14a-12

Ophthotech Corporation

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- x No fee required.
- o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies: _____
 - (2) Aggregate number of securities to which transaction applies: _____
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): _____
 - (4) Proposed maximum aggregate value of transaction: _____
 - (5) Total fee paid: _____
- o Fee paid previously with preliminary materials.
- o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid: _____
 - (2) Form, Schedule or Registration Statement No.: _____
 - (3) Filing Party: _____
 - (4) Date Filed: _____

**OPHTHOTECH CORPORATION
One Penn Plaza, 19th Floor
New York, NY 10119**

SUPPLEMENT TO NOTICE OF ANNUAL MEETING OF STOCKHOLDERS AND
DEFINITIVE PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON THURSDAY, JUNE 2, 2016

On May 9, 2016, Ophthotech Corporation (the "Company") filed a Current Report on Form 8-K disclosing that on May 6, 2016, Nicholas Galakatos, Ph.D. resigned from the Board of Directors of the Company. The Company's Board of Directors is divided into three classes, with members of each class serving staggered three-year terms. Dr. Galakatos was not standing for election at the Company's 2016 annual meeting of stockholders because as a class I director his term would otherwise have expired at the Company's annual meeting of stockholders to be held in 2017. The resignation by Dr. Galakatos does not affect the directors nominated for election at the 2016 annual meeting of stockholders.

In connection with the resignation by Dr. Galakatos, the Company's Board of Directors appointed existing director Michael Ross, Ph.D. to replace Dr. Galakatos as a member of the Audit Committee and existing director David Redlick to replace Dr. Galakatos as a member and chair of the Compensation Committee.

